Arvinas Inc

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW HAVEN, Conn., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will participate in two upcoming investor conferences:

Arvinas to Participate in Upcoming Investor Conferences

Arvinas, Inc. (NASDAQ:ARVN ) Q3 2024 Earnings Conference Call October 30, 2024 8:00 AM ET Company Participants Jeff Ball - Chief Financial Officer John Houston - Chief Executive Officer, President and Chairperson Noah Berkowitz - Chief Medical Officer Andrew Sake - Chief Financial Officer Angela Cacace - Chief Scientific Officer Conference Call Participants Akash Tewari - Jefferies Brad Canino - Stifel Etzer Darout - BMO Capital Markets Ellie Merle - UBS Derek Archila - Wells Fargo Li Watsek - Cantor Ted Tenthoff - Bipolar Sandler Tazeen Ahmad - Bank of America Michael Schmidt - Guggenheim Tyler Van Buren - TD Cowen Jonathan Miller - Evercore ISI Yigal Nochomovitz - Citigroup Matthew Biegler - Oppenheimer Operator Thank you for standing by. At this time, I'd like to welcome everyone to Arvinas Third Quarter 2024 Earnings Call.

Arvinas, Inc. (ARVN) Q3 2024 Earnings Call Transcript

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $1.18 per share a year ago.

Arvinas, Inc. (ARVN) Reports Q3 Loss, Tops Revenue Estimates

– On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data for the PROTAC LRRK2 degrader ARV-102 demonstrating that LRRK2 degradation affects biomarkers in the CSF – - $1.1 billion in cash, cash equivalents and marketable securities as of Sept. 30, 2024 - – Company to host conference call today at 8:00 a.m.

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that employees from 16 states participated in the Company's third annual “Arvinas Impact Day,” a company-wide day of service where employees joined forces to give back to their communities, engaging in various volunteer activities that made a tangible difference across the Greater New Haven area and beyond.

Arvinas Gives Back to Local Greater New Haven Community in Third Annual Impact Day

NEW HAVEN, Conn., Oct. 21, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2024 financial results and provide a corporate update during a live webcast on Wednesday, October 30, 2024, at 8:00 a.m. ET.

Arvinas to Report Third Quarter 2024 Financial Results and Provide Corporate Update and Host Webcast on Wednesday, October 30, 2024

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.49 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.25 per share a year ago.

Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

Cigna

HubSpot

Spirit Airlines

Flex Lng Ltd

Grifols, S.A.

CBRE Global Real Estate Income Fund

Inter & Co Inc

KKR Real Estate Finance Trust

Polestar Automotive Holding UK PLC

Rubrik Inc

We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. Polestar Automotive Holding is seen as continuing to struggle with missed targets, high losses, and debt raises, warranting a sell. HubSpot faces volatility post-Google acquisition plans, while Grifols considers privatization amid debt concerns and shareholder issues.

Undercovered Dozen: Spirit Airlines, HubSpot, Cigna, First Quantum Minerals +

Arvinas (ARVN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Arvinas (ARVN) Surges 9.2%: Is This an Indication of Further Gains?

- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn.

Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer

– Preclinical data for ARV-393 presented at t he European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –

Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2

NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced Ian Taylor, Ph.D. has been promoted to President of Research and Development and Angela Cacace, Ph.D. has also been promoted and will succeed Dr. Taylor as Chief Scientific Officer of the company. Dr. Taylor and Dr. Cacace will assume these new roles effective immediately and report to John Houston, Ph.D., Chairperson, President and Chief Executive Officer.

Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D.

Axsome Therapeutics

Cytokinetics

Intellia Therapeutics

Novartis

Pfizer

Regeneron Pharmaceuticals

Viking Therapeutics

Wells Fargo recently tagged numerous midcap biotech/biopharma stocks as potential buyout targets. There are many names on this list that have been mentioned as acquisition candidates in the past and that could find themselves in Big Pharma's sights. I highlight three of my favorite equities on Wells Fargo's report that I currently hold in my personal accounts in the paragraphs below.

3 Of My Favorite Names On Wells Fargo's Biotech Buyout List

NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2 clinical trial with vepdegestrant, a novel investigational oral PROteolysis Targeting Chimera (PROTAC®) ER degrader, in combination with Pfizer's atirmociclib (PF-07220060), an investigational CDK4 inhibitor, were accepted for presentation at the 2024 American Society of Clinical Oncology Annual Congress held May 31 to June 4, 2024, in Chicago, IL.

Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress

– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 –

Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)

NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress held from May 15-17, 2024, in Berlin, Germany. Vepdegestrant is a novel investigational PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with early and locally advanced or metastatic ER positive/human epidermal growth factor receptor 2 (HER2) negative (ER+/HER2-) breast cancer.

Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress

Arvinas, Inc. (ARVN) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to loss of $1.54 per share a year ago.

Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates

– Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting –

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update

Arvinas (ARVN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Earnings Season Could Be Great for Arvinas (ARVN)

Arvinas (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?

Arvinas (ARVN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

NEW HAVEN, Conn., April 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced the appointment of Randy Teel, Ph.D., to the newly created role of Chief Business Officer. Dr. Teel currently serves as Arvinas' interim Chief Financial Officer and Treasurer, and in his new role, he will remain a member of the Executive Committee reporting to Chairperson, President and Chief Executive Officer, John Houston, Ph.D. Dr. Teel will remain in these interim roles at Arvinas while the board of directors continues its search for a permanent Chief Financial Officer and Treasurer.

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer

Arvinas' shares have experienced a significant increase, up more than 75% since November 2023, due to the success of its lead asset, vepdegestrant, in breast cancer studies. Arvinas entered into a strategic license agreement with Novartis for the development and commercialization of ARV-766, its second-generation PROTAC androgen receptor degrader for prostate cancer. Novartis is a force in prostate thanks to its recently-approved drug pluvicto, which has multi-billion peak revenue potential. As such, Arvinas may have found its perfect partner.

Arvinas And Novartis Partnering On Prostate Cancer Protein Degrader Is A Win-Win Situation

Arvinas Inc (NASDAQ: ARVN) is in the green at writing after announcing a deal worth over $1.0 billion with Novartis (SWX: NOVN). Details of Arvinas – Novartis agreement Novartis will pay $150 million to the pharmaceutical company up front.

Arvinas inks over $1.0 billion deal with Novartis

Janux Therapeutics

Biotech stocks heated Thursday as Novartis scooped up a licensing pact with Arvinas and Janux was said to be exploring strategic options.

Biotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options

News for Arvinas Inc Stock (ARVN)